Showing 2751-2760 of 3597 results for "".
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog
- IPC Comorbidities Symposium Covers Depression, Obesity, and Morehttps://practicaldermatology.com/news/IPC-Comorbidities-Symposium-Covers-Depression-Obesity-More/2471517/Comorbidities of psoriasis were the focus of the International Psoriasis Council’s meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “Syposium: Preventing Comorbig Disease in Psoriasis” started with presentations on depression and card
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://practicaldermatology.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr